After proven benefit for patients with advanced HER2-positive breast cancer, anti-HER2 therapies were evaluated for early disease.(6,7) In 2005, Piccart-Gebhart et al. evaluated treatment with one to two years of trastuzumab in HER2- positive early breast cancer with prior neoadjuvant or adjuvant therapy, showing an overall survival benefit of one year against the observational group.(8). This evidence concerns the gene ERBB2 and breast cancer.